ClinicalTrials.gg
RecruitingNCT06682429TR-2Updated Nov 19, 2026

Telerehabilitation In The Home After Stroke

An interventional study of Telerehabilitation in Stroke, sponsored by University of California, Los Angeles. Recruiting at 32 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 19, 2026Eligibility revisedSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Stroke by University of California, Los Angeles — 4 open to participants now, 4 under way, none of them phase 3. Stroke · University of California, Los Angeles.

Planned enrollment
5th of 19
202 · median 25
Started
2025
with 1 other
No phase
9 of 20
3 open now
Registered
19th of 20
by date

Among the 20 studies in Stroke by University of California, Los Angeles, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, and was the 19th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 20 studies in Stroke by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Stroke by University of California, Los Angeles, or all of them as a file.
02

Study summary

The purpose of this research study is to evaluate whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone.

Patients with arm weakness due to stroke that happened in the past 90-270 days will be randomized into one of two groups: [1] TR and usual care; [2] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes/day of activities targeting arm function, 6 days a week for 6 weeks.

Read the detailed description

This is a randomized, assessor-blinded study that involves the use of telerehabilitation to deliver additional therapy for persons with stroke. Patients with arm weakness due to stroke that happened in the past 90-270 days will be randomized into one of two groups: [1] TR and usual care; [2] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes/day of activities targeting arm function, 6 days a week 6-8 weeks. The hypothesis of this study is patients receiving TR in addition to their usual care will have significantly greater recovery of arm function compared to patients receiving usual care alone.

Study participation will last approximately 8 months and includes 4 in-person visits. At these visits, patients will undergo a variety of assessments including tests of arm function and a single MRI scan of the brain. Patients undergoing TR will receive arm motor training, which consists of 36 sessions of assigned exercises, games, and stroke education; these total 70 minutes in length and occur 6 days a week for 6 weeks; TR subjects will also continue usual care. Patients in the usual care group only will not engage in TR but will instead continue all of the therapies recommended by their medical team. At the end of the study, participants in the usual care group will be offered TR.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • stroke
  • rehabilitation
  • telehealth
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-85 years at the time of randomization
  2. The index stroke was radiologically verified, due to ischemia or intracerebral hemorrhage (ICH), and had time of onset 90-270 days prior to randomization
  3. The stroke caused upper extremity deficits as defined by Action Research Arm Test score 14-44 (out of 57) at Baseline Visit 1
  4. Box \& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit 1
  5. Able to successfully perform all 3 rehabilitation exercise test examples (simple commands) at Baseline Visit 1
  6. and behavioral contract signed by the subject (i.e., no surrogate consent)

Exclusion criteria

Exclusion Criteria:

  1. A major, active, coexistent neurological, psychiatric, or medical disease that reduces the likelihood that a subject will be able to comply with all study procedures
  2. Unable or unwilling to perform study procedures/therapy, or expectation of noncompliance with study procedures/therapy, or expectation that subject cannot participate in all study visits
  3. A diagnosis (apart from the index stroke) that substantially affects paretic arm function
  4. Severe depression, defined as Geriatric Depression Scale Score >10/15 at Baseline Visit 1
  5. Significant cognitive impairment, defined as score \<22 [a lower score is permitted if due to aphasia and allowed by the site PI]
  6. Deficits in communication that interfere with reasonable study participation
  7. Severe UE spasticity, defined as presence of contracture or modified Ashworth Scale score=4 in either biceps or pectoralis
  8. Modified Rankin Scale score was >2 prior to the index stroke
  9. A new symptomatic stroke has occurred since the index stroke, or a separate stroke occurred within 30 days prior to the index stroke
  10. Lacking visual acuity, with or without corrective lens, of 20/50 or better in at least one eye
  11. \< 9 months
  12. Pregnant; women of must have a negative pregnancy test
  13. Botulinum toxin to the paretic arm: received in the prior 3 months OR expected by the 8-Month Visit
  14. Concurrent enrollment in another therapy-based study where the duration of the investigational therapy's activity is likely to occur during the subject's participation in the study
  15. Subject lacks sufficient English or Spanish to comply with study procedures and TR instructions
  16. Expectation that subject will not have a single domicile address during the 6 weeks of therapy that is within 1.5-hr drive of the central study site [this can be waived at the discretion of the site PI]
  17. to MRI
  18. On isolation precautions, e.g., due to active COVID-19
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
202 participants (estimated)

Study arms

  • No intervention
    Usual Care

    Participants in the usual care group will receive no TR, but will continue with the recommendations made by their care team. All participants in this group will be offered TR at the end of the study.

  • Experimental
    Telerehabilitation + Usual Care

    Patients will receive 36 telerehabilitation sessions targeting arm motor function in addition to their usual care. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently.

    Device: Telerehabilitation

Interventions

  • DeviceTelerehabilitation

    The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.

06

What researchers measure

Primary outcomes

  1. Change in Action Research Arm Test (ARAT) Score from Baseline to 2 Months

    The ARAT scale measures arm function using a scale that runs from 0 to 57 points, with higher numbers reflecting better arm function.

    Time frame: 2 months

Secondary outcomes

  1. Change in modified Rankin Scale (mRS) Score from Baseline to 2 Months

    The mRS scale measures global function using a scale that runs from 0 to 6 points, with lower numbers reflecting better global function.

    Time frame: 2 months

07

Study locations

24 of 32 sites recruiting
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
    Not yet recruiting
  • Rancho Los Amigos Research Institute
    Downey, California 90242, United States
    Recruiting
    • Jason Garcia · Contactjasong@ranchoresearch.org · (562)385-6939
    • Charles Liu, MD · Principal investigator
    • Shailesh Kantak, PhD · Sub investigator
    • Susan Shaw, MD · Sub investigator
  • University of California, Irvine
    Irvine, California 92868, United States
    Recruiting
    • Lucy Dodakian, OT · Contactldodak@hs.uci.edu · (949)824-8748
    • An Do, MD · Principal investigator
  • Keck Medical Center of USC
    Los Angeles, California 90033, United States
    Recruiting
    • Stuti Chakraborty · Contactstuticha@usc.edu · (626)642-8213
    • Sook-Lei Liew, PhD · Principal investigator
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
    Recruiting
    • Ryan McCarville · Contacttr2trial@mednet.ucla.edu · (424)522-7874
    • Steven C Cramer, MD, FAAN, FAHA · Principal investigator
  • Casa Colina Hospital and Centers for Healthcare
    Pomona, California 91767, United States
    Recruiting
  • Hillcrest Medical Center at UC San Diego Health
    San Diego, California 92103, United States
    Recruiting
  • Medstar Health Research Institute
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Brooks Rehabilitation Hospital
    Jacksonville, Florida 32216, United States
    Recruiting
    • Taisiya Matev · Contacttaisiya.matev@brooksrehab.org · (904)345-8973
    • Lauren Shapiro, MD · Principal investigator
    • Mark Bowden, PT, PhD · Sub investigator
  • Jackson Memorial Hospital Christine E. Lynn Rehabilitation Center
    Miami, Florida 33136, United States
    Not yet recruiting
    • Dinorah Rodriguez, RN · Contactdrodriguez5@med.miami.edu · (305)243-2797
    • Sony Isaac, MD · Principal investigator
    • Leslie Morse, DO · Sub investigator
  • Emory Rehabilitation Hospital
    Atlanta, Georgia 30322, United States
    Recruiting
    • Susan Murphy · Contactsmurph7@emory.edu · (404)712-1928
    • Michael Borich, PhD, PT · Principal investigator
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Recruiting
    • Sasha Moores · Contactsmoores@kumc.edu · (913)588-2697
    • Sandra Billinger, PhD, PT · Principal investigator
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Spaulding Rehabilitation Hospital
    Charlestown, Massachusetts 02129, United States
    Recruiting
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
    Recruiting
  • University of Michigan University Hospital
    Ann Arbor, Michigan 48108, United States
    Recruiting
    • Danny Shin · Contactddshin@umich.edu · (734)615-3904
    • Chandramouli Krishnan, PhD · Principal investigator
    • Edward Claflin, MD · Sub investigator
  • Yale New Haven Hospital
    New Haven, New York 06515, United States
    Not yet recruiting
    • Michael Kampp · Contactmichael.kampp@yale.edu · 877-985-3637
    • Rebecca Blumenreich, MD · Principal investigator
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • Karolina Roszkowski · Contactkarolina.roszkowski@mountsinai.org · 929-637-5818
    • David Putrino, PhD · Principal investigator
    • Christopher Kellner, MD · Sub investigator
    • Jenna Tosto, PT · Sub investigator
  • NYP Columbia University Medical Center
    New York, New York 10032, United States
    Recruiting
  • Westchester Medical Center
    Valhalla, New York 10595, United States
    Not yet recruiting
  • Burke Rehabilitation
    White Plains, New York 10605, United States
    Not yet recruiting
    • Josette Hartnett, MPH · Contactjohartnett@burke.org · 914-597-2367
    • Andrew Abdou, DO · Principal investigator
  • University of North Carolina Medical Center
    Chapel Hill, North Carolina 27514, United States
    Recruiting
    • Jessica Cassidy · Contactjcassidy@med.unc.edu · (919)843-5774
    • Jessica Cassidy, PhD, PT · Principal investigator
  • Duke University Hospital
    Durham, North Carolina 27710, United States
    Recruiting
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
    Recruiting
    • Colin Drury · Contactdrurycd@ucmail.uc.edu · (513)558-7656
    • Oluwole Awosika, MD · Principal investigator
  • MetroHealth Old Brooklyn Health Center
    Cleveland, Ohio 44109, United States
    Not yet recruiting
    • Krissy Hansen, PT · Contactkhansen1@metrohealth.org · (216)957-3584
    • David Cunningham, PhD · Principal investigator
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    Recruiting
    • Heidi Poppendeck · Contactpoppenh@ccf.org · (216)704-3675
    • Christina Xia, MD · Principal investigator
  • Jefferson Moss Rehabilitation Research Institute
    Elkins Park, Pennsylvania 19027, United States
    Recruiting
    • Paria Arfa-Fatollahkhani · Contacttr2trial@mednet.ucla.edu · (215)663-6400
    • Dylan Edwards, PhD · Principal investigator
    • Alberto Esquenazi, MD · Sub investigator
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • Michelle Shanahan · Contactshanaha@musc.edu · 843-792-7751
    • Parneet Grewal, MD · Principal investigator
    • Michelle Woodbury, PhD · Sub investigator
  • The Institute for Rehabilitation and Research (TIRR) Memorial Hermann
    Houston, Texas 77030, United States
    Not yet recruiting
  • UT Houston/Memorial Hermann Hospital TMC
    Houston, Texas 77030, United States
    Recruiting
  • University of Utah Health
    Salt Lake City, Utah 84132, United States
    Recruiting
    • Amit Sethi, MD · Contactamit.sethi@utah.edu · (801)585-9292
    • Amit Sethi, MD · Principal investigator
  • University of Virginia Health
    Charlottesville, Virginia 22903, United States
    Not yet recruiting
    • Andrew Weko · ContactCRX3QP@uvahealth.org · 434-297-6777
    • Chad Aldridge, PT, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Non-PHI data will be shared with appropriate parties after the study is completed and published.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Any time after September 30, 2030

Access criteria: Appropriate parties with appropriate intention for use of the data, starting 9/30/30, with access to PHI-free data.

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2029, 46 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 46 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2024
First posted
Nov 12, 2024
StartActual
Aug 22, 2025
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added. Cleveland Clinic Foundation is now Recruiting
Show 5 added (5 United States)
  • Barrow Neurological Institute · Phoenix, United States
  • Yale New Haven Hospital · New Haven, United States
  • Westchester Medical Center · Valhalla, United States
  • Burke Rehabilitation · White Plains, United States
  • University of Virginia Health · Charlottesville, United States
across 2 updates, Oct 9, 2026 – Nov 19, 2026
Eligibility
Maximum age 80 Years→85 Years; 3 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAge 18-8085 years at the time of randomization
  • EditedThe index stroke was radiologically verified, due to ischemia or intracerebral hemorrhage (ICH), and had time of onset 120±3090-270 days prior to randomization
  • EditedThe stroke caused upper extremity deficits as defined by Action Research Arm Test score 1814-44 (out of 57) at Baseline Visit 1
Oct 26, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Medical University of South Carolina · Charleston, United StatesContact r•••@musc.edu · •••8045→s•••@musc.edu · •••7751
Nov 5, 2026
Show all 4 updates
  1. Nov 19, 2026
    5 sites added
    Show 5 added (5 United States)
    • Barrow Neurological Institute · Phoenix, United States
    • Yale New Haven Hospital · New Haven, United States
    • Westchester Medical Center · Valhalla, United States
    • Burke Rehabilitation · White Plains, United States
    • University of Virginia Health · Charlottesville, United States
  2. Nov 5, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Medical University of South Carolina · Charleston, United StatesContact r•••@musc.edu · •••8045→s•••@musc.edu · •••7751
  3. Oct 26, 2026
    Eligibility Maximum age 80 Years→85 Years; 3 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAge 18-8085 years at the time of randomization
    • EditedThe index stroke was radiologically verified, due to ischemia or intracerebral hemorrhage (ICH), and had time of onset 120±3090-270 days prior to randomization
    • EditedThe stroke caused upper extremity deficits as defined by Action Research Arm Test score 1814-44 (out of 57) at Baseline Visit 1
    + 1 other change: description
  4. Oct 9, 2026
    Cleveland Clinic Foundation is now Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06682429
Collaborators
Moss Rehabilitation Research Institute, National Institute of Neurological Disorders and Stroke (NINDS)
Responsible party
Steven C. Cramer, MD, FAAN, FAHA, FASNR (Professor, University of California, Los Angeles) — Principal investigator
First posted
Nov 12, 2024
Start date
Aug 22, 2025
Primary completion
Jun 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Steven Cramer, MD
Contact
tr2trial@mednet.ucla.edu
(424)522-7874
Steven Cramer, MD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion